The authors also reported that treatment with an SGLT2 inhibitor compared to the placebo led to a 19% reduction in cardiovascular mortality, a 12% reduction in 3-point MACE, and a 32% reduction in CHF hospitalizations. This evidence concerns the gene SLC5A2 and congestive heart failure.